This is a working overview of intranasal delivery, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-03 and is reviewed periodically as new material appears.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
During the question and answer section of the paper, Moniz, it is alleged, "startled" Fulton by inquiring if this procedure might be extended to human subjects suffering from mental illness. Fulton stated that he replied that while possible in theory, it was surely "too formidable" an intervention for use on humans.
Portal venous systems A portal venous system is a series of veins or venules that directly connect two capillary beds. The two systems in verebrates are the hepatic portal system, and the hypophyseal portal system.
A transdermal gel was formulated to address this but plasma concentrations were undetectable. In cats oral tramadol at 6 mg/kg provides equivalent analgesia to intramuscular tramadol at 4 mg/kg. One study comparing tramadol to meperidine found tramadol to be more effective at providing analgesia for cats undergoing ovariohysterectomy. A study looking at treatment of osteoarthritis in geriatric cats found owner-reported improvements but also significant adverse effects. Reported adverse effects of tramadol include: diarrhoea, dysphoria, anorexia, tachycardia, pyrexia, tachypnoea, and increased levels of serotonin leading to agitation. Tramadol has the potential to cause serotonin syndrome when administered alongside serotonin re-uptake inhibitors, monoamine oxidase inhibitors, and tricyclic antidepressants. In horses, tramadol is ineffective by itself. Two studies looking at intravenous tramadol found it provided no thermal or mechanical antinociception, another study looking at oral tramadol for chronic laminitis found it provided minimal analgesia, and another study looking at intraarticular tramadol found it provided no post-operative analgesia following arthroscopy; however, when administered with paracetamol (acetaminophen) tramadol provides short-acting mechanical antinociception and when administered with ketamine oral tramadol provides adequate analgesia for chronic laminitis. Based on this evidence tramadol is not recommended to be provided on its own for analgesia in horses.
Samba(in German) - Gambian Physician, former president Of Gambia Football Federation, former World Health Organization WHO Regional Director For Africa. Bai Lamin Jobe(in German - Former Minister Of Works, Transportation And infrastructure. Samba D. Bah (in German) - Former DG State intelligence Service. Ousman A. Bah(in German) - Former Minister Of Communication and Technology. Mary Sey - Jurist, former justice of The Supreme court Of Gambia. Fatou Mass Jobe-Njie - former Minister of Tourism and Culture. Pa Jallow (Diplomat)(in German) - Former DG State intelligence service. Cherno Jallow – Lawyer and Judge. Justice of the Supreme Court of the Gambia, former attorney general of the British Virgin Islands, Gambia Hamat Bah – Politician. Current Minister of Tourism and Culture; leader of the National Reconciliation Party (NRP), Gambia Omar A. Jallow – Politician. former Minister of Agriculture, leader of the People's Progressive Party, Gambia Halifa Sallah – former Special Advisor to the president on Governance and the spokesperson for President Adama Barrow's administration, former National Assembly Minority Leader, Secretary-general of the People's Democratic Organisation for Independence and Socialism, Gambia Momodou Lamin Sedat Jobe - Diplomat, former Gambian foreign minister Mama Kandeh- leader opposition Gambia Democratic Congress, and former parliamentarian Bubacarr Bah - Professor of Mathematics, German Research Chair of Mathematics with specialization in Data Science at AIMS South Africa. Haddy Jallow- actress, Gambia.
A wide range of potential structures have been reported. These all feature the classical organophosphorus core (sometimes with the P=O replaced with P=S or P=Se), which is most commonly depicted as being a phosphoramidate or phosphonate, usually fluorinated (cf. monofluorophosphate). The organic groups are subject to more variety; however, a common substituent is phosgene oxime or analogues thereof. This is a potent chemical weapon in its own right, specifically as a nettle agent, and would be expected to increase the harm done by the Novichok agent. Many claimed structures from this group also contain cross-linking agent motifs which may covalently bind to the acetylcholinesterase enzyme's active site in several places, perhaps explaining the rapid denaturing of the enzyme that is claimed to be characteristic of the Novichok agents. Zoran Radić, a chemist at the University of California, San Diego, performed an in silico docking study with Mirzayanov's version of the A-232 structure against the active site of the acetylcholinesterase enzyme. The model predicted a tight fit with high binding affinity and formation of a covalent bond to a serine residue in the active site, with a similar binding mode to established nerve agents such as sarin and soman.
Sources: en.wikipedia.org
has to be changed compared to the simple SIR model.) Early models of this type have been used to model the spread of the black death in Europe. Extensions of this model have been used to incorporate, e.g., effects of nonpharmaceutical interventions such as social distancing.
In 2004, a special issue of The International Journal of Sociology and Social Policy was published that was edited by Steven P. Schacht, who participated in the SSSP session. The special issue contained ten articles analyzing his research and his multiple contributions as a social activist and scholar. The authors of these articles call for sociologists and others to move beyond criticism of Humphrey's research methodologies in the tearoom study, and instead to focus on his pioneering contributions to the study of sexuality, participant-observation as method, development of sociological theory, and his work as a social activist and advocate for marginalized sexual identities.
There should be a strong presumption against forcibly removing a democratic regime. But that presumption might be overcome if the government in question poses a grave threat to human rights, or is likely to destroy democracy itself by shutting down future political competition.
=== Research === 1ST-103 – undefined mechanism of action [140] LXM-5 – undefined mechanism of action [141] Parkinson's disease siRNA therapeutic - Argo Biopharma – RNA interference [142] Research programme: Parkinson's disease therapeutics - Beech Tree Labs (PD-A) – undefined mechanism of action – parkinsonian disorders [143]
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.